Dysfunctional HDLs are Associated with a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk: A Nested-Case Control Study.
暂无分享,去创建一个
D. Corella | R. Elosua | M. Fitó | M. Martínez-González | L. Serra-Majem | C. Lassale | E. Ros | R. Estruch | O. Castañer | M. Ruíz-Canela | J. Salas-Salvadó | E. Gómez-Gracia | F. Arós | M. Fiol | J. Lapetra | J. Sorlí | M. Bulló | X. Pintó | Á. Alonso-Gómez | M. Soria-Florido | Á. Hernáez | R. Elosúa | J. Salas‐Salvadó
[1] D. Corella,et al. Association Between Fatty Acids of Blood Cell Membranes and Incidence of Coronary Heart Disease: A Case-Control Study Nested in the PREDIMED Trial , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[2] A. Tall,et al. Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[3] P. Joshi,et al. Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events. , 2018, Journal of the American College of Cardiology.
[4] J. Martínez,et al. Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90. , 2018, The New England journal of medicine.
[5] P. Whelton,et al. Response by Beddhu et al to Letters Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control". , 2018, Circulation.
[6] Quan Zhou,et al. High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis , 2017, Lipids in Health and Disease.
[7] C. Wanner,et al. HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients. , 2017, Journal of the American Society of Nephrology : JASN.
[8] D. Fliser,et al. HDL Cholesterol Efflux Capacity and Cardiovascular Events in Patients With Chronic Kidney Disease. , 2017, Journal of the American College of Cardiology.
[9] Y. Zhang,et al. Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study. , 2016, Atherosclerosis.
[10] Changhao Wu,et al. Prognostic Usefulness of Serum Cholesterol Efflux Capacity in Patients With Coronary Artery Disease. , 2016, The American journal of cardiology.
[11] S. Bakker,et al. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. , 2016, Atherosclerosis.
[12] J. Heinecke,et al. Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL , 2015, Current opinion in lipidology.
[13] R. Erbel,et al. Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading. , 2015, Journal of the American College of Cardiology.
[14] D. Rader,et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.
[15] B. Kleuser,et al. The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality , 2015, Biological chemistry.
[16] A. Khera,et al. HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.
[17] A. Tselepis,et al. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) bound to LDL and HDL. , 2014, Current pharmaceutical design.
[18] Solid-Timi Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014 .
[19] Darrel P Francis,et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients , 2014, BMJ : British Medical Journal.
[20] R. Erbel,et al. HDL-Bound Sphingosine 1-Phosphate (S1P) Predicts the Severity of Coronary Artery Atherosclerosis , 2014, Cellular Physiology and Biochemistry.
[21] P. Pais,et al. Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.
[22] A. Khera,et al. Anti‐oxidative and cholesterol efflux capacities of high‐density lipoprotein are reduced in ischaemic cardiomyopathy , 2013, European journal of heart failure.
[23] P. Barter,et al. Translation of High-Density Lipoprotein Function Into Clinical Practice: Current Prospects and Future Challenges , 2013, Circulation.
[24] S. Hazen,et al. Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[25] J. Lekakis,et al. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. , 2012, Journal of the American College of Cardiology.
[26] H. Berrougui,et al. Health benefits of high-density lipoproteins in preventing cardiovascular diseases. , 2012, Journal of clinical lipidology.
[27] John Spertus,et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.
[28] Zahi A Fayad,et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. , 2012, Circulation.
[29] Dolores Corella,et al. Cohort profile: design and methods of the PREDIMED study. , 2012, International journal of epidemiology.
[30] T. Lüscher,et al. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease , 2012, EMBO molecular medicine.
[31] Swneke D. Bailey,et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. , 2012, Biochimica et biophysica acta.
[32] R. Bittman,et al. A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol , 2011, Journal of Lipid Research.
[33] P. Giral,et al. Stimulation of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human Macrophages Is ABCA1-Dependent but ABCG1-Independent , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[34] A. Kontush,et al. Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.
[35] G. Norata,et al. Modified HDL: biological and physiopathological consequences. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[36] G. Lewis,et al. HDL metabolism in hypertriglyceridemic states: an overview. , 1999, Clinica chimica acta; international journal of clinical chemistry.
[37] A E Becker,et al. Atherosclerotic plaque rupture--pathologic basis of plaque stability and instability. , 1999, Cardiovascular research.
[38] R. Stocker,et al. Oxidation of High Density Lipoproteins , 1998, The Journal of Biological Chemistry.
[39] A G Babiker,et al. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. , 1991, Statistics in medicine.
[40] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.
[41] P. Barter,et al. Dysfunctional HDL and atherosclerotic cardiovascular disease , 2016, Nature Reviews Cardiology.
[42] Dylan L. Steen,et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014, JAMA.
[43] Edinburgh Research Explorer Mendelian randomization of blood lipids for coronary heart disease , 2022 .